News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- Gene Expression and Treatment Prognosis in Maligna...
- Researchers Confirm Chromosome Deletion Among Meso...
- CDC Reports That Deaths From Mesothelioma Are Stil...
- MesotheliomaHelp.net Announces Expanded Informatio...
- United Nations Assures Staff That Renovations Are ...
- House Renovators and Home Repairmen at High Risk f...
- Advance in Cancer Diagnosis
- Secretary Tells Panel Museums Are Safe
- Emission Of Airborne Fibers From Mechanically Impa...
- Asbestos-link Cancer Rates Revealed
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
Wednesday, May 6, 2009
Prior research has identified osteopontin (SPP1) as a potential tumor marker for malignant mesothelioma, as well as for other cancers, but little is understood about the biological activity responsible for this function. Molecular analysis of osteopontin has identified three specific isoforms of the protein, which are known as SPP1-A, SPP1-B and SPP1-C, but the relationship between these isoforms and carcinogenesis is also poorly understood. To learn more about these relationships, researchers from New York University’s School of Medicine conducted a study on tissue samples extracted from the resected tissue of patients with malignant mesothelioma and then compared their findings to a control group of healthy tissue. The researchers found that all of the isoforms of SPP1 were present in normal tissues, but that SPP1-A and SPP1-B were significantly up-regulated in the mesothelioma tissue, but SPP1-C was not. This was also the case when the researchers compared cases of primary mesothelioma to cases of recurrent mesothelioma, which led the researchers to conclude that SPP1-A and SPP1-B may be useful serum markers for mesothelioma diagnosis.
The researchers also looked at the tumorigenic activity of osteopontin and found that both SPP1-A and SPP1-B were associated with pro-tumorigenic activity, while SPP1-C was not. The researchers hypothesize that because the only structural difference between SPP1-A and SPP1-C is an exon that encodes an oligopeptide, future research may be able to develop a specific inhibitor to SPP1-A’s pro-tumorigenic activity. Such a development could be very beneficial to improving the efficacy of mesothelioma treatments.
This study was published in Biochemical and Biophysical Research Communications, under the title of “Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.”
Labels: diagnosis, mesothelioma
posted by Joseph DiCastro at 2:26 PM
